Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits
Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits
Merck & Co Inc (NYSE:MRK) has reportedly secured a significant legal victory as the 3rd U.S. Circuit Court of Appeals upheld the dismissal of nearly 1,200 lawsuits concerning its Zostavax shingles vaccine.
據報道，默沙東公司（NYSE:MRK）在其皰疹帶狀皰疹疫苗 Zostavax 上獲得了重大的法律勝利，第三巡迴上訴法院維持了撤銷近 1,200 起訴案件的裁決。
The court ruled that U.S. District Judge Harvey Bartle did not exceed his authority when he dismissed cases for failing to provide required clinical test results in response to a Lone Pine order.
法院裁定，美國地區法官哈維·巴特爾未超出職權範圍，因被告未能在對 Lone Pine 訂單的回應中提供必要的臨床測試結果而撤銷了這些案件。
Mass torts increasingly use these orders to demand initial evidence, such as medical records, to substantiate claims early on.
集體訴訟越來越多地使用這些命令來要求初始證據，例如醫療記錄，以儘早驗證索賠。
Also Read: What's Going On With Merck Stock On Monday?
還閱讀：默沙東股票週一怎麼了？
Judge Bartle initiated the Lone Pine order in early 2022 following Merck's success in five bellwether cases, where plaintiffs failed to demonstrate through a PCR test that the vaccine, rather than prior exposure to the chickenpox virus, caused their shingles.
在默沙東成功進行 5 起分界審判案件之後，巴特爾法官於 2022 年初發布了 Lone Pine 訂單，在此期間原告未能通過 PCR 檢測證明疫苗而非先前暴露於水痘病毒導致了帶狀皰疹。
Reuters added that the order mandated all remaining plaintiffs to produce similar clinical evidence to support their claims.
據路透社報道，該命令要求所有剩餘的原告提供類似的臨床證據來支持其索賠。
Plaintiffs' attorneys argued that PCR tests were not standard practice for diagnosing shingles, leading to a lack of available test results.
原告律師主張，PCR 測試不是診斷帶狀皰疹的標準做法，導致缺乏可用的測試結果。
Merck countered that the cases lacked merit without conclusive evidence linking the vaccine to shingles.
默沙東反駁說，這些案件缺乏證明疫苗與帶狀皰疹之間存在確定性聯繫的證據。
Despite opposition, Judge Bartle dismissed all cases, emphasizing the failure to provide adequate scientific backing for their claims.
儘管遭到反對，巴特爾法官撤銷了所有案件，強調未能提供足夠的科學依據支持其索賠。
The 3rd Circuit upheld Bartle's decision, stating that plaintiffs had sufficient opportunity to justify their claims without PCR tests but failed to present alternative methodologies or scientific studies.
第三巡迴上訴法院維持了巴特爾的決定，稱原告有足夠的機會在沒有PCR測試的情況下證明其索賠，但未能提出替代方法或科學研究。
The court affirmed Bartle's discretion to manage the multidistrict litigation efficiently, albeit with acknowledgment of limits to judicial discretion.
儘管承認司法裁量權的侷限性，法院確認了巴特爾有效地管理多地訴訟的權利。
Price Action: MRK stock is down 2.18% at $123.14 at last check Thursday.
價格走勢：MRK 股票週四最後交易時下跌 2.18%，至 123.14 美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本內容部分使用人工智能工具生成，並經Benzinga編輯審核發佈。
- FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug.
- FDA 拒絕批准默沙東-第一三共合作的肺癌藥。
Image: Merck
圖片：默沙東
譯文內容由第三人軟體翻譯。